Shares of Kodiak Sciences plunged in trading on February 23 after the company announced its Phase II/III study of a novel antibody biopolymer conjugate failed to hit the mark in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.
Regeneron and Sanofi announced that a late-stage trial for the blockbuster anti-inflammatory drug Dupixent for patients with chronic spontaneous urticaria (CSU) was halted due to futility.
Although the COVID-19 pandemic has hit companies unevenly, some biopharma firms that have produced new drugs or vaccines against the disease have shown big spikes in drug sales. BioSpace reviewed five companies that produced non-vaccine treatments for COVID-19.
At 6 months of age, babies born to mothers vaccinated against COVID-19 during pregnancy are more likely to have antibodies against the virus in their blood than babies born to unvaccinated mothers who were infected while pregnant, a small study suggests. Additionally, contracting COVID-19 late in pregnancy is linked with a higher risk for obstetric complications, new data suggest.
Regeneron Pharmaceuticals Inc. on Feb. 4 reported fourth-quarter 2021 revenue that beat analysts’ estimates, boosted by demand for the blockbuster drugs Dupixent and Eylea, coupled with higher sales of the company’s COVID-19 therapy.
After 50 years, Sanofi is giving itself a bit of a branding make-over with a new logo and a restructuring of the France-based company’s corporate umbrella in support of its three-year-old “Play to Win” strategy.
Regeneron Pharmaceuticals and Sanofi’s anti-inflammatory drug Dupixent (dupilumab) has shown to be effective against five types of type 2 inflammations, with more indications expected to surface soon.
Regeneron Pharmaceuticals and the company’s partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of the anti-cancer drug Libtayo in patients with advanced cervical cancer.
The U.S. health regulator revised on Jan. 24 the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.
The Omicron variant can survive longer than earlier versions of the coronavirus on plastic surfaces and human skin, Japanese researchers found in laboratory tests. Additionally, new research shows users of rapid antigen tests to detect COVID-19 should swab their nostrils as directed by the manufacturer and not swab the throat or cheek instead.
